Delcath Systems (NASDAQ:DCTH) Issues Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Delcath Systems (NASDAQ:DCTH) posted its quarterly earnings data on Tuesday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.19, RTT News reports. Delcath Systems had a negative return on equity of 1,007.65% and a negative net margin of 2,308.86%. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. During the same period in the prior year, the company earned ($0.86) EPS.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $5.09 on Thursday. The business’s 50 day moving average is $4.34 and its two-hundred day moving average is $3.84. The company has a current ratio of 3.30, a quick ratio of 3.11 and a debt-to-equity ratio of 0.08. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $7.99.

Insider Buying and Selling at Delcath Systems

In other news, Director Gil Aharon acquired 26,882 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was acquired at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the acquisition, the director now directly owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 21.10% of the stock is currently owned by insiders.

Institutional Trading of Delcath Systems

Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its holdings in Delcath Systems by 107.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock valued at $26,000 after purchasing an additional 2,419 shares in the last quarter. Geode Capital Management LLC boosted its position in Delcath Systems by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 62,733 shares of the company’s stock valued at $361,000 after buying an additional 2,851 shares during the last quarter. BlackRock Inc. boosted its position in Delcath Systems by 22.3% in the 1st quarter. BlackRock Inc. now owns 16,632 shares of the company’s stock valued at $96,000 after buying an additional 3,032 shares during the last quarter. Cibc World Market Inc. boosted its position in Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after buying an additional 3,432 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Delcath Systems by 77.7% in the 2nd quarter. Renaissance Technologies LLC now owns 21,500 shares of the company’s stock valued at $125,000 after buying an additional 9,400 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on DCTH shares. HC Wainwright upped their target price on Delcath Systems from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. StockNews.com raised shares of Delcath Systems to a “sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, Delcath Systems currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.